| Metric | Value (₹ Cr) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 1.5K | 1.3% | 5.8% |
| Total Income | 1.6K | 0.5% | 7.2% |
| Expenditure | 1.3K | 2.9% | 6.5% |
| PBT | 283.92 | 9.2% | 10.6% |
| Net Profit | 183.68 | 14.8% | 12.3% |
| OPM | 21.11% | 3.32pp | 14.20pp |
| NPM | 11.69% | 2.10pp | 0.53pp |
| EPS | 11.15 | 14.8% | 12.3% |
Gland Pharma Reports Strong Q2 FY26 Results with Revenue Up 6% and PAT Up 12% YoY
03 Nov 2025 · 3 Nov 2025, 04:55 pm
Summary
Gland Pharma Limited, a generic injectable-focused pharmaceutical company, announced its financial results for the second quarter ended September 30, 2025. The company reported a 6% year-on-year increase in revenue and a 12% year-on-year increase in PAT.
Key Highlights
- 1
Quarterly revenue increased by 6% year-on-year; Half yearly revenues increased by 7%
- 2
Quarterly R&D investments increase to ¥ 614 million against ¥ 460 million in previous quarter
- 3
Quarterly EBITDA increased by 6% year-on-year; Half yearly EBITDA increased by 21%
- 4
Quarterly adj. EBITDA increased by 13% year-on-year; Half yearly adj. EBITDA increased by 26%
- 5
Quarterly PAT increased by 12% year-on-year; Half yearly PAT increased by 30%
Management Comments
Srinivas Sadu
Executive Chairman of Gland Pharma
Gland Pharma delivered a strong first half of FY26, with Revenue growth of 7% and PAT up by 30% YoY. We expect stronger momentum in the second half, driven by new launches and Cenexi’s recovery.
Shyamakant Giri
Chief Executive Officer of Gland Pharma
For the quarter, Gland Pharma’s core business maintained its profitable growth trajectory with strong margin expansion. Encouragingly for consolidated business, we saw year-over-year improvement during the Q2 FY26 with USA growing by 10% and Europe by 16%, supported by a 21% top-line increase in Cenexi.
Informational and educational content only. Not investment advice.